via Tokyo University of Science
Scientists modified “mesenchymal stem cells” to carry anti-cancer drugs and deliver them to target cancers
Targeting drugs to cancer tissues is a major challenge in cancer treatment. Mesenchymal stem cells (MSCs) are known for their ability to find and target tumor cells in the body, but using MSCs for drug delivery has been tricky, because upon loading with drugs, MSCs lose their viability and migratory ability. Now, researchers from Tokyo University of Science have successfully modified MSCs to deliver large quantities of anti-cancer drugs in a targeted manner to developing cancer cells.
As humans evolve, cancer also evolves in parallel, making the race for finding efficient treatment methods for cancer patients challenging and constant. In addition to designing drugs for treatment, the delivery of these drugs to targeted organs is also a major challenge faced by the cancer research community.
Many research groups have tried to develop techniques to efficiently deliver anti-cancer drugs to tumors. An interesting way utilizes a distinct group of cells in our body, the mesenchymal stem cells (MSCs), which have a special ability to find and move towards tumors. This means that theoretically, we can load these “tumor-homing” MSCs with anti-cancer drugs and use them to hinder cancer progression. However, pilot studies show that the anti-cancer drug loading capacity of MSCs is limited, and they tend to lose their ability to target and reach tumor cells upon drug loading.
In a recent study published in Journal of Controlled Release, researchers from Japan, led by Dr. Kosuke Kusamori and Professor Makiya Nishikawa from Tokyo University of Science, sought to find out how to modify MSCs to bypass these problems. Dr. Kusamori, Assistant Professor in the University’s Department of Pharmacy says, “We wondered if the answer to our dilemma of modifying mesenchymal stem cells with an anticancer drug was to exploit the property of mesenchymal stem cells to accumulate in tumor tissues.”
Using the well-known “avidin-biotin complex” (ABC) method, the researchers used liposomes-cellular lipid bags popularly used as drug delivery systems-to carry the anti-cancer drug doxorubicin (DOX) to the surface of specific mouse MSCs. They named these lipid bags carrying DOX “DOX-Lips.”
The researchers found that the MSCs loaded with DOX-Lips could carry and selectively target mouse colon cancer cells growing in artificial cultures in the lab. These modified MSCs could not only carry a significant amount of the drug, but also efficiently deliver it inside the target cancer cells. To test if this feature is replicated in a living system, they used a mouse model with skin and lung cancer. They found that in both cases, DOX-Lips were able to efficiently reach cancer cells and release the drug into the cytoplasm of the cancer cells. The researchers concluded that the modified MSCs could completely suppress tumor growth in mouse models.
There are several advantages to this new method. First, the process is relatively faster than previously known methods. As Yukiya Takayama, a doctoral student in Professor Nishikawa’s lab and a co-author of the study observes, “The relatively short duration of the ABC method made it possible to quickly modify the cell surface with DOX-Lips and avoid cell damage.”
Second, this method did not affect the process of cell attachment to cancer cells, thereby ensuring maximum efficiency in drug delivery. Third, contrary to previous observations that lipid bags of only a certain size can be used to deliver drugs, this new study suggests that the size of the lipid bags very likely does not affect drug delivery; this finding can be exploited to deliver many different doses of drugs as well.
The combination of the ABC method and the use of Lips thus seems to be the answer to the researchers’ dilemma. Professor Nishikawa is excited about these results. “We have succeeded in developing a new targeted cancer therapy,” he observes. “Mesenchymal stem cells can migrate to brain tumors and minute cancer lesions that are otherwise inaccessible to conventional drug delivery systems. Our method may thus be effective against intractable cancers,” Nishikawa says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Modified stem cells
- Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
The administration of LV-RAG1 includes reduced intensity conditioning prior to reinfusion of the patients’ own gene-modified blood stem cells. “The patient was administered LV-RAG1 without any ...
- Induced Pluripotent Stem Cell (iPSC) Global...
DUBLIN, July 28, 2022 /PRNewswire/ -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added to ...
- Editas treats first patient in sickle cell trial as FDA lifts partial hold
The sickle cell therapy being studied is the second CRISPR-based medicine that Editas has advanced into clinical testing. Initial trial results could come as soon as the end of this year.
- Cell Therapy Market to Generate $35.95 billion, Regenerative Therapy and 3D Printing to Remain in Limelight
The cell therapy market is set to grow at an exponential CAGR and will shape patient care in many sectors, and its growth may be reduced only by the inability to control ...
- Insulin Production by Human Embryonic Stem Cells
Cells were grown in knockout Dulbecco s modified Eagle s medium (Gibco, Grand Island, NY) supplemented with 20% serum replacement (Gibco), 1% nonessential amino acids (Gibco), 0.1 mmol/l 2 ...
Go deeper with Google Headlines on:
Modified stem cells
Go deeper with Bing News on:
Mesenchymal stem cells
- Stem cell therapy could become cheaper and widely available
UTS researchers have developed a 3D printed system that could enable high quality, wide-scale stem cell production in Australia at a lower cost.
- First time in Israel: Adult stem cells transplanted in toddler with rare skin disease
The first transplantation of the mesenchymal stem cells (MSC) was given as part of compassionate treatment to a two-and-a-half-year-old boy suffering from epidermolysis bullosa (EB).
- Technology Insight: Adult Mesenchymal Stem Cells for Osteoarthritis Therapy
Techniques that cause multipotent adult mesenchymal stem cells (MSCs) to differentiate into cells of the chondrogenic lineage have led to a variety of experimental strategies to investigate ...
- Mesenchymal Stem Cells Market Trends, High CAGR, Industry Size, New Innovations, Future Scope and Forecast 2031
Jul 27, 2022 (AmericaNewsHour) -- Kenneth Research, in its repository of market research reports, has recently added a report titled Mesenchymal Stem Cells Market market, that emphasizes on the ...
- ISSCA Announces the Program Agenda of Regenerative Medicine World Congress 2022
The International Society for Stem Cell Application (ISSCA) is hosting the most anticipated regenerative medicine event of he year – Regenerative Medicine World Congress 2022. The congress will take ...